The U.S. Trustee and several insurance firms objected to confirmation of Johnson & Johnson’s proposed $10 billion bankruptcy plan, citing the U.S. Supreme Court’s 2024 ruling that dismantled Purdue Pharma’s opioid settlement.
U.S. Trustee, Insurers, Object to J&J’s $10B Talc Bankruptcy Plan
The objections, filed ahead of a key hearing on whether to confirm the Chapter 11 plan, cite the Supreme Court’s decision in Harrington v. Purdue Pharma, which invalidated nonconsensual releases in the $6 billion bankruptcy plan granted to Purdue’s founders, the Sacklers.
By
Amanda Bronstad
This premium content is locked for The Bankruptcy Strategist subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Bankruptcy Strategist
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
